{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T10:49:54Z","timestamp":1791456594160,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Fabry disease (FD) is an X-linked inherited lysosomal storage disorder caused by deficiency of the enzyme \u03b1-galactosidase A. This study describes the long-term evolution of retinal findings in genetically confirmed FD patients, who have been receiving enzyme replacement therapy (ERT) or pharmacological chaperone therapy (PCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included 42 eyes of 21 patients, who underwent comprehensive ophthalmic examination including best-corrected visual acuity (BCVA) testing, tonometry, slit-lamp biomicroscopy of the anterior eye segment, fundus examination and spectral-domain optical coherence tomography (OCT) imaging. Longitudinal analysis focused on the central retinal thickness (CRT), peripapillary retinal nerve fiber layer (RNFL) thickness, intraretinal hyperreflective foci (HRF), and retinal vessel tortuosity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median follow-up period of 6.5 years, BCVA remained stable in all patients. Serum lyso-globotriaosylceramide (lyso-Gb3) levels demonstrated strong correlations with intraretinal HRF and retinal vessel tortuosity but no significant change during the observation period was observed. Longitudinal assessment showed no significant change of HRF, retinal vessel tortuosity or CRT over time, whereas a significant reduction of RNFL thickness was observed, although these values remained within the normal range.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Long-term treatment with ERT or PCT in FD is associated with a largely stable retinal phenotype. Retinal imaging parameters remain structurally preserved over time, with only mild RNFL thinning observed, suggesting limited progressive retinal neurodegeneration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04654-2","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:04:47Z","timestamp":1791428687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal assessment of the retinal phenotype in patients with Fabry disease undergoing continuous enzyme replacement and\/or chaperone therapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Annabelle","family":"Volk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Birtel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mautone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"K\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Muschol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-0478","authenticated-orcid":false,"given":"Yevgeniya","family":"Atiskova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"issue":"1\u20132","key":"4654_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jns.2014.06.029","volume":"344","author":"R El-Abassi","year":"2014","unstructured":"El-Abassi R, Singhal D, England JD. Fabry\u2019s disease. J Neurol Sci. 2014;344(1\u20132):5\u201319.","journal-title":"J Neurol Sci"},{"issue":"8","key":"4654_CR2","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.12669\/pjms.38.8.7063","volume":"38","author":"S Saeed","year":"2022","unstructured":"Saeed S, Imazio M. Fabry disease: Definition, Incidence, Clinical presentations and Treatment - Focus on cardiac involvement. Pak J Med Sci. 2022;38(8):2337\u201344.","journal-title":"Pak J Med Sci"},{"issue":"9","key":"4654_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1474-4422(06)70548-8","volume":"5","author":"A Fellgiebel","year":"2006","unstructured":"Fellgiebel A, Muller MJ, Ginsberg L. CNS manifestations of Fabry\u2019s disease. Lancet Neurol. 2006;5(9):791\u20135.","journal-title":"Lancet Neurol"},{"issue":"10","key":"4654_CR4","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","volume":"28","author":"A Linhart","year":"2007","unstructured":"Linhart A, Kampmann C, Zamorano JL, Sunder-Plassmann G, Beck M, Mehta A, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J. 2007;28(10):1228\u201335.","journal-title":"Eur Heart J"},{"issue":"26","key":"4654_CR5","first-page":"440","volume":"106","author":"B Hoffmann","year":"2009","unstructured":"Hoffmann B, Mayatepek E. Fabry disease-often seen, rarely diagnosed. Dtsch Arztebl Int. 2009;106(26):440\u20137.","journal-title":"Dtsch Arztebl Int"},{"issue":"29","key":"4654_CR6","doi-asserted-by":"publisher","first-page":"e7387","DOI":"10.1097\/MD.0000000000007387","volume":"96","author":"JH Choi","year":"2017","unstructured":"Choi JH, Lee BH, Heo SH, Kim GH, Kim YM, Kim DS, et al. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype. Med (Baltim). 2017;96(29):e7387.","journal-title":"Med (Baltim)"},{"key":"4654_CR7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4654_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1076\/opge.24.3.129.15609","volume":"24","author":"C Orssaud","year":"2003","unstructured":"Orssaud C, Dufier J, Germain D. Ocular manifestations in Fabry disease: a survey of 32 hemizygous male patients. Ophthalmic Genet. 2003;24(3):129\u201339.","journal-title":"Ophthalmic Genet"},{"key":"4654_CR9","first-page":"15","volume":"13","author":"K Hangartner","year":"2023","unstructured":"Hangartner K, Bajka A, Wiest MRJ, Sidhu S, Toro MD, Maloca PM, Zweifel SA. Assessment of Retinal Vessel Tortuosity Index in Patients with Fabry Disease Using Optical Coherence Tomography Angiography (OCTA). Diagnostics (Basel). 2023;13:15.","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"4654_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/bjophthalmol-2014-306433","volume":"100","author":"L van der Tol","year":"2016","unstructured":"van der Tol L, Sminia ML, Hollak CE, Biegstraaten M. Cornea verticillata supports a diagnosis of Fabry disease in non-classical phenotypes: results from the Dutch cohort and a systematic review. Br J Ophthalmol. 2016;100(1):3\u20138.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"4654_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s13023-019-1267-2","volume":"14","author":"Y Atiskova","year":"2019","unstructured":"Atiskova Y, Rassuli R, Koehn AF, Golsari A, Wagenfeld L, du Moulin M, et al. Retinal hyperreflective foci in Fabry disease. Orphanet J Rare Dis. 2019;14(1):296.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"4654_CR12","doi-asserted-by":"publisher","first-page":"e0233460","DOI":"10.1371\/journal.pone.0233460","volume":"15","author":"W Mauhin","year":"2020","unstructured":"Mauhin W, Benveniste O, Amelin D, Montagner C, Lamari F, Caillaud C, et al. Cornea verticillata and acroparesthesia efficiently discriminate clusters of severity in Fabry disease. PLoS ONE. 2020;15(5):e0233460.","journal-title":"PLoS ONE"},{"key":"4654_CR13","doi-asserted-by":"crossref","unstructured":"Gambini G, Scartozzi L, Giannuzzi F, Carla MM, Boselli F, Caporossi T et al. Ophthalmic manifestations in fabry disease: updated review. J Pers Med. 2023;13(6).","DOI":"10.3390\/jpm13060904"},{"issue":"3","key":"4654_CR14","doi-asserted-by":"publisher","first-page":"e0120814","DOI":"10.1371\/journal.pone.0120814","volume":"10","author":"S Pitz","year":"2015","unstructured":"Pitz S, Kalkum G, Arash L, Karabul N, Sodi A, Larroque S, et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PLoS ONE. 2015;10(3):e0120814.","journal-title":"PLoS ONE"},{"issue":"1","key":"4654_CR15","doi-asserted-by":"publisher","first-page":"2226909","DOI":"10.1080\/07853890.2023.2226909","volume":"55","author":"Y Wu","year":"2023","unstructured":"Wu Y, Zhang W, Yao X, Song W, Zhao Y, Yuan Y, Zhang W. Investigation of ocular involvement in patients with Fabry disease. Ann Med. 2023;55(1):2226909.","journal-title":"Ann Med"},{"issue":"3","key":"4654_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/13816810.2022.2025607","volume":"43","author":"O Yanik","year":"2022","unstructured":"Yanik O, Ciki K, Ozmert E, Sivri S. Vascular and structural analyses of retinal and choroidal alterations in Fabry disease: the effect of hyperreflective foci and retinal vascular tortuosity. Ophthalmic Genet. 2022;43(3):344\u201353.","journal-title":"Ophthalmic Genet"},{"issue":"2","key":"4654_CR17","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1111\/j.1755-3768.2012.02576.x","volume":"91","author":"A Sodi","year":"2013","unstructured":"Sodi A, Guarducci M, Vauthier L, Ioannidis AS, Pitz S, Abbruzzese G, et al. Computer assisted evaluation of retinal vessels tortuosity in Fabry disease. Acta Ophthalmol. 2013;91(2):e113\u20139.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"4654_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1080\/01658107.2024.2301921","volume":"48","author":"SS Moon","year":"2024","unstructured":"Moon SS, Ovens CA, Reid G, Fraser CL. SD-OCT Imaging of Macular Changes in Fabry Disease: A Case Report. Neuroophthalmology. 2024;48(3):198\u2013203.","journal-title":"Neuroophthalmology"},{"issue":"2","key":"4654_CR19","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1136\/bjo.2006.100602","volume":"91","author":"A Sodi","year":"2007","unstructured":"Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry\u2019s disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91(2):210\u20134.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"4654_CR20","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s13023-021-02080-0","volume":"16","author":"Y Atiskova","year":"2021","unstructured":"Atiskova Y, Wildner J, Spitzer MS, Aries C, Muschol N, Dulz S. Retinal vessel tortuosity as a prognostic marker for disease severity in Fabry disease. Orphanet J Rare Dis. 2021;16(1):485.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"4654_CR21","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12325-024-03041-2","volume":"42","author":"R Mignani","year":"2025","unstructured":"Mignani R, Biagini E, Cianci V, Pieruzzi F, Pisani A, Tuttolomondo A, Pieroni M. Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice. Adv Ther. 2025;42(2):597\u2013635.","journal-title":"Adv Ther"},{"issue":"9","key":"4654_CR22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","volume":"103","author":"A Mehta","year":"2010","unstructured":"Mehta A, Beck M, Eyskens F, Feliciani C, Kantola I, Ramaswami U, et al. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641\u201359.","journal-title":"QJM"},{"issue":"1","key":"4654_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s40360-017-0152-7","volume":"18","author":"K Tsuboi","year":"2017","unstructured":"Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naive Fabry disease patients. BMC Pharmacol Toxicol. 2017;18(1):43.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"4654_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ymgme.2022.10.005","volume":"137","author":"C Tondel","year":"2022","unstructured":"Tondel C, Thurberg BL, DasMahapatra P, Lyn N, Maski M, Batista JL, et al. Clinical relevance of globotriaosylceramide accumulation in Fabry disease and the effect of agalsidase beta in affected tissues. Mol Genet Metab. 2022;137(4):328\u201341.","journal-title":"Mol Genet Metab"},{"key":"4654_CR25","doi-asserted-by":"crossref","unstructured":"Weidemann F, Jovanovic A, Herrmann K, Vardarli I. Chaperone Therapy in fabry disease. Int J Mol Sci. 2022;23(3).","DOI":"10.3390\/ijms23031887"},{"issue":"4","key":"4654_CR26","doi-asserted-by":"publisher","first-page":"C1076","DOI":"10.1152\/ajpcell.00426.2005","volume":"290","author":"GH Yam","year":"2006","unstructured":"Yam GH, Bosshard N, Zuber C, Steinmann B, Roth J. Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. Am J Physiol Cell Physiol. 2006;290(4):C1076\u201382.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"6","key":"4654_CR27","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry\u2019s Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"4654_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"issue":"6","key":"4654_CR29","doi-asserted-by":"publisher","first-page":"e0213329","DOI":"10.1371\/journal.pone.0213329","volume":"14","author":"L Michaud","year":"2019","unstructured":"Michaud L. Longitudinal study on ocular manifestations in a cohort of patients with Fabry disease. PLoS ONE. 2019;14(6):e0213329.","journal-title":"PLoS ONE"},{"issue":"2","key":"4654_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ymgme.2017.07.002","volume":"123","author":"A Nowak","year":"2018","unstructured":"Nowak A, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC. Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease. Mol Genet Metab. 2018;123(2):148\u201353.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"4654_CR31","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Wyatt KM, Henley W, Nikolaou V, Waldek S, Hughes DA, et al. Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis. 2014;37(6):969\u201378.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"4654_CR32","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","volume":"23","author":"DG Bichet","year":"2021","unstructured":"Bichet DG, Aerts JM, Auray-Blais C, Maruyama H, Mehta AB, Skuban N, et al. Assessment of plasma lyso-Gb(3) for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease. Genet Med. 2021;23(1):192\u2013201.","journal-title":"Genet Med"},{"key":"4654_CR33","doi-asserted-by":"crossref","unstructured":"Braun F, Abed A, Sellung D, Rogg M, Woidy M, Eikrem O et al. Accumulation of alpha-synuclein mediates podocyte injury in fabry nephropathy. J Clin Invest. 2023;133(11).","DOI":"10.1172\/JCI157782"},{"issue":"8","key":"4654_CR34","doi-asserted-by":"publisher","first-page":"e032734","DOI":"10.1161\/JAHA.123.032734","volume":"13","author":"A Frustaci","year":"2024","unstructured":"Frustaci A, Verardo R, Galea N, Alfarano M, Magnocavallo M, Marchitelli L, et al. Long-Term Clinical-Pathologic Results of Enzyme Replacement Therapy in Prehypertrophic Fabry Disease Cardiomyopathy. J Am Heart Assoc. 2024;13(8):e032734.","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"4654_CR35","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/jhg.2016.78","volume":"61","author":"JH Kim","year":"2016","unstructured":"Kim JH, Lee BH, Hyang Cho J, Kang E, Choi JH, Kim GH, Yoo HW. Long-term enzyme replacement therapy for Fabry disease: efficacy and unmet needs in cardiac and renal outcomes. J Hum Genet. 2016;61(11):923\u20139.","journal-title":"J Hum Genet"},{"key":"4654_CR36","doi-asserted-by":"publisher","first-page":"1307558","DOI":"10.3389\/fimmu.2024.1307558","volume":"15","author":"B Laffer","year":"2024","unstructured":"Laffer B, Lenders M, Ehlers-Jeske E, Heidenreich K, Brand E, Kohl J. Complement activation and cellular inflammation in Fabry disease patients despite enzyme replacement therapy. Front Immunol. 2024;15:1307558.","journal-title":"Front Immunol"},{"issue":"1","key":"4654_CR37","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s13023-024-03503-4","volume":"19","author":"M Lenders","year":"2024","unstructured":"Lenders M, Nowak A, Cybulla M, Kaufeld J, Kohn AF, Muschol NM, et al. Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease. Orphanet J Rare Dis. 2024;19(1):490.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"4654_CR38","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","volume":"28","author":"E Riccio","year":"2020","unstructured":"Riccio E, Zanfardino M, Ferreri L, Santoro C, Cocozza S, Capuano I, et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Eur J Hum Genet. 2020;28(12):1662\u20138.","journal-title":"Eur J Hum Genet"},{"key":"4654_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE. Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis. 2013;8:47.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"4654_CR40","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1536\/ihj.17-688","volume":"60","author":"M Tsujiuchi","year":"2019","unstructured":"Tsujiuchi M, Ebato M, Maezawa H, Mizukami T, Nogi A, Ikeda N, et al. Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease. Int Heart J. 2019;60(1):208\u201314.","journal-title":"Int Heart J"},{"issue":"4","key":"4654_CR41","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, Stork S, Breunig F, Beer M, Sommer C, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274(4):331\u201341.","journal-title":"J Intern Med"},{"issue":"3","key":"4654_CR42","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s10545-014-9677-8","volume":"37","author":"SM Rombach","year":"2014","unstructured":"Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. J Inherit Metab Dis. 2014;37(3):341\u201352.","journal-title":"J Inherit Metab Dis"},{"key":"4654_CR43","doi-asserted-by":"publisher","first-page":"9573587","DOI":"10.1155\/joph\/9573587","volume":"2025","author":"MN Mat Nor","year":"2025","unstructured":"Mat Nor MN, Green CR, Squirrell D, Acosta ML. Retinal Hyperreflective Foci Are Biomarkers of Ocular Disease: A Scoping Review With Evidence From Humans and Insights From Animal Models. J Ophthalmol. 2025;2025:9573587.","journal-title":"J Ophthalmol"},{"issue":"8","key":"4654_CR44","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/s41433-025-03721-5","volume":"39","author":"D Bacherini","year":"2025","unstructured":"Bacherini D, Mercuri S, Sodi A, Gambini G, Rizzo C, Rizzo S, et al. Inner retinal hyper-reflective foci number correlates with flood-illumination adaptive optics ophthalmoscopy grading and systemic organ involvement in patients with Fabry disease. Eye (Lond). 2025;39(8):1578\u201383.","journal-title":"Eye (Lond)"},{"issue":"1","key":"4654_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-025-03627-1","volume":"20","author":"Y Li","year":"2025","unstructured":"Li Y, Zhou X, Li J, Zhao Y, Yuan Y, Yang B, et al. Deep learning assisted retinal microvasculature assessment and cerebral small vessel disease in Fabry disease. Orphanet J Rare Dis. 2025;20(1):158.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"4654_CR46","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/aos.12588","volume":"93","author":"HC Fledelius","year":"2015","unstructured":"Fledelius HC, Sandfeld L, Rasmussen AK, Madsen CV, Feldt-Rasmussen U. Ophthalmic experience over 10 years in an observational nationwide Danish cohort of Fabry patients with access to enzyme replacement. Acta Ophthalmol. 2015;93(3):258\u201364.","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"4654_CR47","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.ophtha.2007.01.023","volume":"114","author":"RS Parikh","year":"2007","unstructured":"Parikh RS, Parikh SR, Sekhar GC, Prabakaran S, Babu JG, Thomas R. Normal age-related decay of retinal nerve fiber layer thickness. Ophthalmology. 2007;114(5):921\u20136.","journal-title":"Ophthalmology"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04654-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04654-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04654-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:55:59Z","timestamp":1791453359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04654-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4654"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04654-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"31 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the medical ethics committee of the \u00c4rztekammer Hamburg (PV5470), Germany. Patients and\/or parents\u2019 consent was obtained.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No consent needed, as only analyzed anonymized data without personal identification are used.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"354"}}